# Role of metabolic crosstalk in determining immunity during tumor progression

> **NIH NIH R01** · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $469,199

## Abstract

PROJECT SUMMARY
Tumor cells and infiltrating immune cells co-evolve during the course of tumor progression, with the immune
system progressively losing its efficacy as tumors advance. Immune cells are highly dependent on cellular
metabolism to manifest their effector functions, but in the tumor microenvironment (TME), ‘metabolic competition’
with rapidly proliferating cancer cells leads to nutrient deprivation alongside increased metabolic waste, both of
which negatively impact immune cell function. Moreover, ‘metabolic symbiosis’ between cancer and immune
cells can promote the acquisition of suppressive immune cell phenotypes, ultimately disfavoring anti-tumor
immunity. These dynamic metabolic interactions are shaped by the niches occupied by cells within the TME.
Thus, the metabolic cross talk between tumor and immune cells over the course of tumor progression can be a
major determinant of immune cell function and, consequently, response to immune-targeted therapies.
Unfortunately, the study of immune cell metabolism and crosstalk in the TME has been very challenging due to
reliance on methods that analyze metabolism in bulk cell populations, which obscures individual cellular diversity,
difficulties in predicting downstream outcomes of metabolic perturbations because of the complexity of the
metabolic network, and the lack of tools to map metabolic alterations in situ. To overcome these challenges, we
developed Compass, a flux balance analysis (FBA) algorithm that applies a network-based analytical approach
to single-cell RNA-sequencing (scRNA-seq) data to predict metabolic states of individual cells in tissue1. We
have applied Compass as well as standard computational methods to the analysis of longitudinal scRNA-seq
data from a pre-clinical murine model of melanoma with the goal of determining the temporal- and tumor-size-
based metabolic alterations in both tumor and infiltrating immune cells during tumor progression.
Our preliminary data indicate that polyamine metabolism is a key hub of metabolic crosstalk between tumor and
immune cells that are either static or dynamic over the course of melanoma tumor progression and that may
occupy distinct tissue niches. We find that CD4+ regulatory T cells (Treg), exhausted CD8+ T cells, and
suppressive myeloid cells upregulate spermine/spermidine acetyltransferase (Sat1), which catalyzes acetylation
of polyamines, with tumor progression. Conversely, a subset of c-Met+ melanoma cells that has features of
stemness is high for polyamine recycling genes. Based on these observations, we hypothesize that that
systems-based analysis of the alterations and crosstalk involving polyamine metabolism in tumor and
immune cells during tumor progression will uncover novel means for therapeutic intervention. We
propose to: 1) Dissect the functional role of polyamine metabolism in immune cells and tumor cells during tumor
progression; 2) Construct a high resolution spatial map of tumor:immune metabolic crosstalk via...

## Key facts

- **NIH application ID:** 10888404
- **Project number:** 5R01CA282794-02
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** ANA C ANDERSON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $469,199
- **Award type:** 5
- **Project period:** 2023-07-14 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10888404

## Citation

> US National Institutes of Health, RePORTER application 10888404, Role of metabolic crosstalk in determining immunity during tumor progression (5R01CA282794-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10888404. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*